Edge Therapeutics

company

About

Edge Therapeutics, a biotechnology company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions.

  • 1 - 10

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$10M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.

It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$66M
Edge Therapeutics has raised a total of $66M in funding over 2 rounds. Their latest funding was raised on Apr 9, 2015 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 9, 2015 Series C $56M 1 Detail
Sep 8, 2014 Debt Financing $10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Edge Therapeutics is funded by 2 investors. Franklin Advisors and Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Franklin Advisors Series C
Hercules Capital Debt Financing